neurim pharmaceuticals | Alzheimer's, ADHD, Autism, Brain Injury Treatment, Mood Disorders New Jersey: The NeuroCognitive Institute

Phase II Clinical Trial for Treatment of Mild Alzheimer’s Disease

U.S. Study Participants Aged 60 to 85 with Mild Dementia Needed TEL AVIV, March 7, 2017 /PRNewswire/ – Neurim Pharmaceuticals Ltd. announced today that they are seeking up to 500 U.S. patients with mild Alzheimer’s Disease for the start of a Phase II Clinical trial of a ne
Read More